Singapore markets closed

Regeneron Pharmaceuticals, Inc. (REGN)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
1,069.74+6.14 (+0.58%)
At close: 04:00PM EDT
1,069.74 0.00 (0.00%)
After hours: 06:50PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 117.87B
Enterprise value 110.05B
Trailing P/E 31.58
Forward P/E 24.45
PEG ratio (5-yr expected) 1.77
Price/sales (ttm)9.31
Price/book (mrq)4.37
Enterprise value/revenue 8.40
Enterprise value/EBITDA 24.19

Trading information

Stock price history

Beta (5Y monthly) 0.13
52-week change 346.56%
S&P500 52-week change 321.83%
52-week high 31,106.16
52-week low 3721.51
50-day moving average 31,026.92
200-day moving average 3931.10

Share statistics

Avg vol (3-month) 3440.84k
Avg vol (10-day) 3375.18k
Shares outstanding 5108.37M
Implied shares outstanding 6110.19M
Float 8103.39M
% held by insiders 11.56%
% held by institutions 189.91%
Shares short (28 Jun 2024) 42.04M
Short ratio (28 Jun 2024) 44.16
Short % of float (28 Jun 2024) 41.95%
Short % of shares outstanding (28 Jun 2024) 41.85%
Shares short (prior month 31 May 2024) 41.75M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Mar 2024

Profitability

Profit margin 29.45%
Operating margin (ttm)24.12%

Management effectiveness

Return on assets (ttm)7.74%
Return on equity (ttm)15.28%

Income statement

Revenue (ttm)13.1B
Revenue per share (ttm)122.57
Quarterly revenue growth (yoy)-0.50%
Gross profit (ttm)N/A
EBITDA 4.42B
Net income avi to common (ttm)3.86B
Diluted EPS (ttm)33.91
Quarterly earnings growth (yoy)-11.70%

Balance sheet

Total cash (mrq)10.52B
Total cash per share (mrq)97.51
Total debt (mrq)2.7B
Total debt/equity (mrq)10.02%
Current ratio (mrq)5.27
Book value per share (mrq)250.15

Cash flow statement

Operating cash flow (ttm)4.74B
Levered free cash flow (ttm)3.03B